Back to Research Hub
ImmunityBio, Inc.
IBRX
$7.25+0.08 (+1.12%)
ImmunityBio, Inc., a clinical-stage biotechnology company, develops therapies and vaccines to treat cancers and infectious diseases. It offers immunotherapy and cell therapy platforms, including antibody cytokine fusion proteins, synthetic immunomodulators, vaccine technologies, natural killer cells, and adaptive (T…
StreetsValue research for ImmunityBio, Inc. (IBRX)
Members get the full report for ImmunityBio, Inc.: a fair value estimate and valuation analysis, economic moat rating, growth and profitability factor grades, a bull and bear investment thesis, analyst price targets, insider and congressional trading activity, and which super investors own the stock.